Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

T. Shaw, Alice; Kim, Dong‐Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crinò, Lucio; Ahn, Myung‐Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin; Blackhall, Fiona; Wu, Yi‐Long; Thomas, Michael; J. O’Byrne, Kenneth; Moro‐Sibilot, Denis; Ross Camidge, D.; Mok, Tony; Hirsh, Vera; J. Riely, Gregory; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; D. Wilner, Keith; A. Jänne, Pasi

doi:10.1056/nejmoa1214886

Public

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

Published in New England Journal of Medicine • Jun 1, 2013

Authors:

Alice T. Shaw

Dong‐Wan Kim

Kazuhiko Nakagawa

Abstract

BACKGROUND: In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to eff...

Subject

Crizotinib

Medicine

Ceritinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!